These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12648505)

  • 1. Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
    Estey E; Giles F; Cortes J; Beran M; Verstovsek S; Garcia-Manero G; Faderl S; Kantarjian H
    Leuk Res; 2003 Jun; 27(6):475-9. PubMed ID: 12648505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
    Estey E; Thall P; Beran M; Kantarjian H; Pierce S; Keating M
    Blood; 1997 Oct; 90(8):2969-77. PubMed ID: 9376577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
    Estey EH; Thall PF; Wang X; Verstovsek S; Cortes J; Kantarjian HM
    Blood; 2003 Nov; 102(9):3097-9. PubMed ID: 12842982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
    Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
    J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
    Viola A; Falco C; D'Elia R; D'Amico MR; Vicari L; Tambaro FP; Correale P; Laudati D; Palmieri S; Ferrara F
    Eur J Haematol; 2007 Jan; 78(1):41-7. PubMed ID: 17042770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
    Jackson G; Taylor P; Smith GM; Marcus R; Smith A; Chu P; Littlewood TJ; Duncombe A; Hutchinson M; Mehta AB; Johnson SA; Carey P; MacKie MJ; Ganly PS; Turner GE; Deane M; Schey S; Brookes J; Tollerfield SM; Wilson MP
    Br J Haematol; 2001 Jan; 112(1):127-37. PubMed ID: 11167793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E; Le QH; Elhamri M; Thomas X
    Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy.
    Estey EH; Thall PF; Reed P; Kantarjian H; Beran M; Pierce S; Keating MJ
    Leukemia; 1999 Jun; 13(6):850-4. PubMed ID: 10360371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213.
    Wells RJ; Arthur DC; Srivastava A; Heerema NA; Le Beau M; Alonzo TA; Buxton AB; Woods WG; Howells WB; Benjamin DR; Betcher DL; Buckley JD; Feig SA; Kim T; Odom LF; Ruymann FB; Smithson WA; Tannous R; Whitt JK; Wolff L; Tjoa T; Lampkin BC
    Leukemia; 2002 Apr; 16(4):601-7. PubMed ID: 11960339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
    van der Heiden PL; Jedema I; Willemze R; Barge RM
    Eur J Haematol; 2006 May; 76(5):409-13. PubMed ID: 16480432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies.
    de Greef GE; van Putten WL; Boogaerts M; Huijgens PC; Verdonck LF; Vellenga E; Theobald M; Jacky E; Löwenberg B; ;
    Br J Haematol; 2005 Jan; 128(2):184-91. PubMed ID: 15638852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
    Kobayashi T; Miyawaki S; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Ohmoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Matsuoka A; Tomonaga M; Ohno R
    J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.